China Universal Asset Management Company’s Pacira BioSciences PCRX Stock Holding History

China Universal Asset Management Company’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$159K	Sell	6,262 -923	-13%	-$21.8K	0.01%	369
2026 Q1	$162K	Buy	7,185 +175	+2%	+$3.89K	0.01%	367
2025 Q4	$181K	Sell	7,010 -866	-11%	-$20.6K	0.01%	352
2025 Q3	$203K	Sell	7,876 -1,424	-15%	-$35K	0.02%	335
2025 Q2	$222K	Buy	9,300 +18	+0.2%	+$454	0.02%	301
2025 Q1	$231K	Sell	9,282 -508	-5%	-$12.2K	0.02%	301
2024 Q4	$184K	Buy	9,790 +918	+10%	+$16.1K	0.02%	333
2024 Q3	$134K	Buy	8,872 +3,404	+62%	+$58.2K	0.01%	332
2024 Q2	$156K	Sell	5,468 -3,462	-39%	-$98.5K	0.02%	269
2024 Q1	$261K	Buy	8,930 +3,557	+66%	+$109K	0.03%	259
2023 Q4	$181K	Buy	5,373 +4,188	+353%	+$123K	0.04%	214
2023 Q3	$36.4K	Buy	1,185 +583	+97%	+$21K	0.01%	250
2023 Q2	$24.1K	Sell	602 -21	-3%	-$868	0.01%	252
2023 Q1	$25.4K	Buy	623 +157	+34%	+$6.25K	0.01%	199
2022 Q4	$18K	Buy	466 +37	+9%	+$1.8K	0.01%	182
2022 Q3	$23K	Buy	+429	New	+$23.9K	0.01%	147

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

China Universal Asset Management Company's PCRX Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Pacira BioSciences (PCRX) stake by 13% in Q2 2026, selling an estimated $21.8K and leaving 6,262 shares worth $159K. The position accounts for 0.01% of the portfolio, ranked #369.

China Universal Asset Management Company first reported a position in PCRX in Q3 2022 and has held it in 16 quarters since. The position peaked at $261K in Q1 2024. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

China Universal Asset Management Company held 6,262 shares of Pacira BioSciences worth $159K as of Q2 2026.
China Universal Asset Management Company sold 923 Pacira BioSciences shares in Q2 2026, an estimated $21.8K.
Pacira BioSciences made up 0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #369 holding.
China Universal Asset Management Company first reported a position in Pacira BioSciences in Q3 2022 and has held it in 16 quarters since.
China Universal Asset Management Company's Pacira BioSciences position peaked at $261K in Q1 2024.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.